Industry layoffs continue to accelerate, this time hitting RA Capital’s biotech incubator, according to Stat. RA Ventures, also known as Raven, is a healthcare accelerator for the prominent life ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Inner Mongolia Yili Industrial Group Co. Ltd. A-0.27% ¥187.79B Yunnan Energy Investment Co. Ltd. A-1.15% ¥10.37B Star Lake Bioscience Co. Ltd. Guangdong Zhaoqing A-0.95% ¥12.26B Lotus Holdings ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Fidelity Select Biotechnology Portfolio earns an Average Process Pillar rating. The primary contributor to the rating is its parent firm's excellent long-term risk-adjusted performance ...

Financial Square Treasury Instruments Fund FST Shares FTIXX 29.42% Financial Square Government Fund FST Shares FGTXX 15.30% ...

SHANGHAI, May 15, 2025 /PRNewswire/ -- On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive AI ...

The International Business School at Brandeis University has offered an MBA degree since 1998. The opportunity for biotechnology students to acquire additional leading edge management skills by ...

Fidelity Advisor Biotechnology Fund earns an Average Process Pillar rating. The leading factor in the rating is its parent firm's superior long-term risk-adjusted performance, as shown by the firm ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging field of treatments that can reprogramme immune cells inside patients ...

For instance, one study of 458 pharmaceutical and biotechnology license agreements found a 7% average royalty. That is attractive as a simple option, but it also ignores the investments and risks ...

DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4 ...